BMP9 ELISA Kit

AVISCERA BIOSCIENCE

HOME ::

Bone Morphogenetic Protein 9 (BMP9) ELISA

Bone morphogenetic protein-9 is a circulating vascular quiescence factor

Angiogenesis is a complex process, requiring a finely tuned balance between numerous stimulatory and inhibitory signals. ALK1 (activin receptor like-kinase 1) is an endothelial-specific type 1 receptor of the transforming growth factor-beta receptor family. Heterozygotes with mutations in the ALK1 gene develop hereditary hemorrhagic telangiectasia type 2 (HHT2). Recently, we reported that bone morphogenetic protein (BMP)9 and BMP10 are specific ligands for ALK1 that potently inhibit microvascular endothelial cell migration and growth. These data lead us to suggest that these factors may play a role in the control of vascular quiescence. To test this hypothesis, we checked their presence in human serum. We found that human serum induced Smad1/5 phosphorylation. To identify the active factor, we tested neutralizing antibodies against BMP members and found that only the anti-BMP9 inhibited serum-induced Smad1/5 phosphorylation. The concentration of circulating BMP9 was found to vary between 2 and 12 ng/mL in sera and plasma from healthy humans, a value well above its EC(50) (50 pg/mL). These data indicated that BMP9 is circulating at a biologically active concentration. We then tested the effects of BMP9 in 2 in vivo angiogenic assays. We found that BMP9 strongly inhibited sprouting angiogenesis in the mouse sponge angiogenesis assay and that BMP9 could inhibit blood circulation in the chicken chorioallantoic membrane assay. Taken together, our results demonstrate that BMP9, circulating under a biologically active form, is a potent antiangiogenic factor that is likely to play a physiological role in the control of adult blood vessel quiescence.

David L, et al. Circ Res. 2008 Apr 25;102(8):914-22. Epub 2008 Feb 28.

BMP9-Induced muscle heterotopic ossification requires changes to the skeletal muscle microenvironment

Heterotopic ossification (HO) is defined as the formation of bone inside soft tissue. Symptoms include joint stiffness, swelling, and pain. Apart from the inherited form, the common traumatic form occurs generally at sites of injury in damaged muscles and is often associated with brain injury. We investigated bone morphogenetic protein 9 (BMP9), which possesses a strong osteoinductive capacity, for its involvement in muscle HO physiopathology. We found that BMP9 had an osteoinductive influence on mouse muscle resident stromal cells by increasing their alkaline phosphatase activity and bone-specific marker expression. Interestingly, BMP9 induced HO only in damaged muscle while BMP2 promoted HO in skeletal muscle regardless of its state. The addition of the soluble form of the ALK1 protein (the BMP9 receptor) significantly inhibited the osteoinductive potential of BMP9 in cells and HO in damaged muscles. BMP9 should thus be considered as a candidate for involvement in HO physiopathology with its activity dependent on the skeletal muscle microenvironment.

Leblanc E, et al. J Bone Miner Res. 2010 Dec 16. [Epub ahead of print]

Haman BMP9 ELISA Kit

Code No.: SK00139-01
Size: 96T
Sensitivity: 3.9 pg/ml
Standard rage: 7.8-500 pg/ml
Sample type: Serum, Cell Cultures
Sample Volume: 100 uL
Intra CV: 4-6%
Inter CV: 8-10%
More Info: Protocol

Human BMP-9/GDF-9 Recombinant
Code No.: 00022-01-100
Size: 100 ug
Price: $360.00 USD
Protein ID:O60383
Gene ID:2661
MW:18 KD
Tag: His Tag on N-Terminus
Expressed: E. Coli
Purity: 95%
Data Sheet: PDF

Name		Code No.	Size	Price ($)
BMP 9 (Human) ELISA Kit	serum,plasma	SK00139-01	96T	360.00
BMP 9/GDF-9 (Human) Recombinant		00022-01-100	100 ug	360.00

Price/availability/specifications subject to change without notice. All products and services are for in vitro research use only. Not for use in or on humans or animals.